Cross-resistance to alkylating agents in multiple myeloma
- 1 September 1983
- Vol. 52 (5) , 786-789
- https://doi.org/10.1002/1097-0142(19830901)52:5<786::aid-cncr2820520505>3.0.co;2-h
Abstract
In order to ascertain whether multiple myeloma patients resistant to one alkylating agent would respond to a second one, high-dose intermittent cyclophosphamide was administered to 12 patients showing resistance to melphalan and prednisone. On the other hand, intermittent melphalan and prednisone treatment was employed in eight myeloma patients resistant to intermittent cyclophosphamide. Only one objective response was achieved among 12 patients on cyclophosphamide therapy, in spite of having employed high doses of this alkylating agent. No responses were achieved with melphalan in the group of cyclophosphamide-resistant patients. The median survival probability was 8.7 months (SD ± 2.9) for all patients after starting the second alkylating agent. These results suggest cross-resistance between melphalan and cyclophosphamide in myeloma. The authors conclude that a single second alkylating agent cannot be recommended as a treatment of patients with multiple myeloma who are truly refractory to one alkylating agent.This publication has 19 references indexed in Scilit:
- The Chemotherapy of Plasma-Cell Myeloma and the Incidence of Acute LeukemiaNew England Journal of Medicine, 1979
- Improved survival of increased-risk myeloma patients on combined triple- alkylating-agent therapy: a study of the CALGBBlood, 1979
- Adriamycin, 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU, NSC 409962), cyclophosphamide plus prednisone (ABC-P) in melphalan-resistant multiple myelomaCancer, 1978
- Clinical Staging and New Therapeutic Approaches in Multiple MyelomaPublished by Springer Nature ,1978
- DOXORUBICIN/B.C.N.U. CHEMOTHERAPY FOR MULTIPLE MYELOMA IN RELAPSEThe Lancet, 1976
- A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survivalCancer, 1975
- 352. Note: Conservatism of the Approximation Σ(O - E) 2 /E in the Logrank Test for Survival Data or Tumor Incidence DataPublished by JSTOR ,1973
- Myelomatosis: Comparison of Melphalan and Cyclophosphamide TherapyBMJ, 1971
- Treatment for Multiple MyelomaJAMA, 1969
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958